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The hormonal control of lymphatic tissue is an important issue for decades but remains largely unexplored. The role 
of estrogens, particularly the 17β-estradiol, is clearly established 
for development of sexual characters, reproduction, and in many 
physiological processes, including cardiovascular function.1–4 The 
biological effects of estradiol are initiated after binding to the ERs 
(estrogen receptors) α and β, belonging to a nuclear receptor sub-
family of ligand-inducible transcription factors.5,6 The endothelial 
function of estradiol is mediated by the receptor ERα.7,8 Estradiol 
induces ER dimerization to promote gene expression regulation by 
binding directly to DNA sequences called estrogen response ele-
ments (EREs)9 or indirectly through protein–protein interactions 
with other DNA-binding transcription factors.10,11 ERα has also 
been localized at the plasma membrane and mediates nongenomic 
signaling pathway leading to ERK and Akt phosphorylation.12,13
Despite an abundant literature demonstrating the beneficial 
effect of estradiol on blood vessels, nothing is known about its 
effects on lymphatic endothelium. Estradiol influences subcu-
taneous tissue and morphology by controlling hyaluronic acid 
synthesis14—a major extracellular matrix ligand for the lymphatic 
endothelial cell (LEC) receptor Lyve-115—suggesting an indi-
rect effect on lymphatic homeostasis. A defect in estrogens has 
been associated with cardiovascular diseases because women 
develop 2 to 3× less cardiovascular diseases before menopause.16 
Importantly, hormonal status has been associated with lymphatic 
disorders, such as lymphedema—a disorder of the lymphatic 
vascular system characterized by impaired lymphatic return and 
swelling of the extremities and an accumulation of fat and fibrosis 
in the arm or the leg.17 Whereas primary lymphedema—a rare dis-
ease—is sex linked with an average ratio of 1 male for 3 females, 
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Objective—Estrogens exert beneficial effect on the blood vascular system. However, their role on the lymphatic system has 
been poorly investigated. We studied the protective effect of the 17β estradiol—the most potent endogenous estrogen—in 
lymphedema—a lymphatic dysfunction, which results in a massive fluid and fat accumulation in the limb.
Approach and Results—Screening of DNA motifs able to mobilize ERs (estrogen receptors) and quantitative real-time 
polymerase chain reaction analysis revealed that estradiol promotes transcriptional activation of lymphangiogenesis-related 
gene expression including VEGF (vascular endothelial growth factor)-D, VEGFR (VEGF receptor)-3, lyve-1, and HASs 
(hyaluronan synthases). Using an original model of secondary lymphedema, we observed a protective effect of estradiol on 
lymphedema by reducing dermal backflow—a representative feature of the pathology. Blocking ERα by tamoxifen—the 
selective estrogen modulator—led to a remodeling of the lymphatic network associated with a strong lymphatic leakage. 
Moreover, the protection of lymphedema by estradiol treatment was abrogated by the endothelial deletion of the receptor 
ERα in Tie2-Cre; ERαlox/lox mice, which exhibit dilated lymphatic vessels. This remodeling correlated with a decrease in 
lymphangiogenic gene expression. In vitro, blocking ERα by tamoxifen in lymphatic endothelial cells decreased cell–cell 
junctions, inhibited migration and sprouting, and resulted in an inhibition of Erk but not of Akt phosphorylation.
Conclusions—Estradiol protection from developing lymphedema is mediated by an activation of its receptor ERα and is 
antagonized by tamoxifen. These findings reveal a new facet of the estrogen influence in the management of the lymphatic 
system and provide more evidence that secondary lymphedema is worsened by hormone therapy.
Visual Overview—An online visual overview is available for this article.  (Arterioscler Thromb Vasc Biol. 2018;38: 
1346-1357. DOI: 10.1161/ATVBAHA.118.310997.)
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the role of hormones, in particular estrogens, has never been inves-
tigated in secondary lymphedema.18,19 Secondary lymphedema 
occurs after cancer treatment or filarial infection.20–22 Although 
it is a common disabling disease causing significant morbidity, 
treatment of lymphedema remains limited and largely ineffective, 
mainly consisting in compression bandaging. In Western coun-
tries, 10% to 15% of women develop lymphedema after breast 
cancer treatment.23–25 Despite the recent improvement of surgi-
cal technics, lymphedema remains a frequent concern of can-
cer surgery. An issue to study secondary lymphedema has been 
hampered by the lack of experimental model. However, mouse-
induced lymphedema has been described after a circumferential 
incision made through the dermis close to the tail base to sever 
the dermal lymphatic vessels.26 In parallel, a primary lymphedema 
has been generated by heterozygous inactivating missense muta-
tions of the gene encoding VEGF (vascular endothelial growth 
factor)-C/D receptor (VEGFR [VEGF receptor]-3).27 In this study, 
we developed a novel model of secondary lymphedema mimick-
ing human pathogenesis of secondary lymphedema to explore 
the effect of estradiol on lymphatic endothelium. We found that 
ERα directly regulates lymphangiogenic genes to promote LEC 
migration and sprouting. We determined that blocking ERα using 
a selective estrogen modulator, such as the tamoxifen, has a detri-
mental effect on lymphatic drainage and function, increasing the 
risk of developing secondary lymphedema. Importantly, the endo-
thelial invalidation of Erα in Tie2-Cre; ERαlox/lox mice showed 
enlarged and abnormal lymphatic vessels associated with a loss of 
estradiol-protective effect on lymphedema. Mechanistically, estra-
diol targeted both gene expression and cell morphology to activate 
LEC Erk signaling suggesting that both nuclear and membrane 
ERα are expressed in LEC.
Altogether, this study suggests the crucial role of estra-
diol—the most predominant estrogen—in restoring a func-
tional lymphatic endothelium after healing. Our work not only 
deciphers the mechanism of the role of estradiol on the LEC 
but involves medical aspects of quality of life of patients with 
breast cancer because no treatment is currently proposed to 
women who developed secondary lymphedema.
Materials and Methods
The authors declare that all supporting data are available within the 
article.
Reagents
Rabbit anti-mouse lyve-1 antibody (RDI-103PA50) was from 
Research Diagnostics, Inc (Concord, MA). Donkey anti-rabbit and rat 
IgGs conjugated with alexa 488, 594 were from TebuBio (TebuBio, 
Le Perray en Yvelines, France). Anti-pSer473Akt, anti-Akt, and 
anti-pThr202/Tyr204 Erk1/2 are from Cell Signaling Technology. 
Anti-phalloidin was from Cytoskeleton (acti-stain phalloidin 488, cat 
PHDG1). Anti–phospho-VEGFR-3 is from Cell Applications, Inc. 
Masson trichrome and Red oil were from Sigma-Aldrich, France. 
Alcyan Blue was from Sigma-Aldrich. Matrigel was from BD. 
Tamoxifen and 17β estradiol are from Sigma-Aldrich. MEK inhibitor 
(PD098059) was from Invivogen.
Mouse Model of Lymphedema
Animal experiments were conducted in accordance with recommen-
dations of the European Convention for the Protection of Vertebrate 
Animals Used for Experimentation. All animal experiments were per-
formed according to the INSERM IACUC guidelines for laboratory 
animal husbandry and have been approved by the local branch Inserm 
Rangueil-Purpan of the Midi-Pyrénées ethics committee. Mice model 
will be restricted to female mice because this article is focusing on 
the effect of estrogen and women breast cancer-associated hormone 
therapy. Lymphedema was established in the left upper limbs of 
6-week-old C57Bl/6 female mice. Bilateral ovariectomy were per-
formed on 4-week-old C57Bl/6 followed by implantation of 60-day 
time release 17β estradiol pellets (0.1 mg estradiol, releasing 80 g/kg 
per day, Innovative Research of America, FL) or tamoxifen (5 mg pel-
let Innovative Research of America, FL) subcutaneously into the back 
of the animals using a sterile trocar or with placebo-releasing pel-
lets. Two weeks after ovariectomy, lymphedema surgical procedure 
is performed. A partial mastectomy of the second mammary gland is 
associated with axillary and brachial lymphadenectomy. Limb size 
was measured in the axillary and distal regions using caliper. Mice 
sustained reproducible edema for a period of >2 weeks.
Quantitative Real-Time Polymerase Chain Reaction
Total cellular RNA was isolated from mouse skin and subcutane-
ous adipose tissue using a TissueLyser (Ultrathurax; IKA, Staufen, 
Germany) in Trizol solution according to manufacturer instructions. 
A total of 1 μg RNA was used to synthesize cDNA using High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Villebon-sur-Yvette, France). The expression of human and murine 
VEGF-C, VEGF-D, VEGFR-3, Lyve-1, HAS1, HAS2, and HAS3 was 
investigated by SYBR Green real-time reverse-transcribed poly-
merase chain reaction (PCR) using the AB 7900 HT Fast Real-Time 
PCR System (Applied Biosystems, Villebon-sur-Yvette, France). 
Each reaction was run with 18S as a reference gene, and all data were 
normalized based on the expression levels of 18S.
Primers
VEGF-C (F): 5′-AGGGAAGAAGTTCCACCATCA-3′; VEGF-C 
(R): 5′-ACAATGCTTCAGTCGATTCGC-3′; VEGF-D (F): 5′- CCT 
ATTGACATGCTGTGGGAT-3′; VEGF-D (R): 5′-GTGGGTTCCTGG 
AGGTAAGAG-3′; VEGFR-3 (F): 5′-TTTATGTCCCACCCCC 
ACTAC-3′; VEGFR-3 (R): 5′-GGCTGAGCTACAAGGCAATCG-3′; 
HAS1 (F): 5′-TAACTACGTCCCCGTGTTGC-3′; HAS1 (R): 
5′-CAGCAAGGTGGTAGGCTTCA-3′; HAS2 (F): 5′- CACTGC 
TGCTGGGACTTGAA-3′; HAS2 (R): 5′- AGACATCATCCC 
ACCGTCCT-3′; HAS3 (F): 5′- AAGGACCGATCTGAAACGCA-3′; 
HAS3 (R): 5′- TACAAGCCCATCTGCCCAAT-3′; 18S (F): 5′-CAACT 
AAGAACGGCCATGCA-3′; 18S (R): 5′-AGCCTGCGGCTTAA 
TTTGAC-3′; Lyve-1 (F): 5′-CAGCACACTAGCCTGGTGTTA-3′; 
Lyve-1 (R): 5′-CGCCCATGATTCTGCATGTAGA-3′. sh RNA ERa 
(TRCN0000003300) is from Sigma-Aldrich.
LEC Isolation
Mice were injected twice with a 2-week interval with incomplete 
Freund adjuvant to develop lymphangioma on diaphragm and liver 
surface. After 4 weeks, tumors are harvested before digestion in 
liberase TM enzyme (Roche) for 10 minutes at 37°C. Supernatants 
were filtered through a 100-μm cell strainer into a 50-mL tube on 
ice. After lysis of erythrocytes (RBC lysis buffer; eBioscience), cells 
were filtered through a 40-μm cell strainer. Cells were incubated with 
Fc-blocking antibody CD16/CD32 for 30 minutes and then stained 
for the following antibodies on ice for 30 minutes: APC-CD31, 
Nonstandard Abbreviations and Acronyms
ER estrogen receptor
ERE estrogen response element
HAS hyaluronan synthase
HDLEC human dermal lymphatic endothelial cell
LEC lymphatic endothelial cell
OVX ovariectomized
PCR polymerase chain reaction
VEGF vascular endothelial growth factor
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CD45-BB515 (BD Pharmingen), and LYVE-1-PE (RD Systems). 
Dead cells were excluded from analysis using live dead violet stain-
ing (Invitrogen).
LEC isolation: Lymphangioma from Tie2-cre; ERαlox/lox mice 
and control littermates were pooled to isolate LEC. LECs were 
then dissociated as described previously using LYVE-1-PE (RD 
Systems:223322), CD45-BB515 (BD Pharmingen:564590), and 
CD31-APC (BD Pharmingen:561814) antibody. LECs (LYVE-1+ 
CD31+ CD45−) were separated using a BD influx cell sorter.
Flow Cytometry Analysis
Lymph nodes from normal, OVX (ovariectomized), estradiol, and 
tamoxifen-treated mice were removed at the time of the lymphedema 
surgery and compared with lymph nodes from the same mice, which 
developed lymphedema 4 weeks after surgery. Lymph nodes were 
dissociated with liberase TM enzyme (Roche) for 10 minutes at 
37°C. Supernatants were filtered through a 100-μm cell strainer into 
a 50-mL tube on ice. After lysis of erythrocytes (RBC lysis buffer; 
eBioscience), cells were filtered through a 40-μm cell strainer. Cells 
were incubated with Fc-blocking antibody CD16/CD32 (Affymetrix, 
eBioscience) for 30 minutes and then stained for the following 
antibodies on ice for 30 minutes: BB515-CD45 (BD Pharmingen), 
CD11b-PEvio770 (Miltenyi Biotec 130-109-365), CD206 PerCP/
Cy5.5 (BioLegend, 141715), and F4/80 (BioLegend, clone BM8). 
Dead cells were excluded from analysis using live dead violet 
staining (Invitrogen). Experiment controls were performed using 
the appropriate control antibodies (APC-IgG2a, 400511; BB515-
IgG2b, 564421; REA control PEvio770, 130-104-616, PerCP/
Cy5.5,400531). Flow cytometry was performed using a BD Fortessa 
cytometer and FACSDiva software analysis.
Intralymphatic FITC-Dextran Injections
Mice were anesthetized with a subcutaneous injection of ketamine (100 
mg/kg) and xylazine (10 mg/kg), and the integrity of the lymphatic vas-
culature of the skin was examined by fluorescence microlymphangiog-
raphy. A fluorescently labeled macromolecule (70 000 kDa fluorescein 
isothiocyanate–dextran-conjugated dextran, 2 mg/mL; Sigma-Aldrich, 
France) was injected into the footpad of the edematous and control leg. 
Because of its large size, the tracer was taken up by the lymphatics 
but was excluded from the blood vasculature. As the lymphatic ves-
sels transported fluorescent tracer, it was clearly visible within dermal 
lymphatic capillaries and collecting vessels, thus providing a clear 
visualization of lymphatic functionality. The integrity of the lymphatic 
vasculature was monitored with a Leica Dmi8 (Leica Microsystems, 
France). Score quantification of the leakage has been established: score 
1 corresponds to no leakage, score 2 corresponds to 1 to 50 m leakage, 
and score 3 corresponds to >50 m leakage.
Whole-Mount Immunostaining
For whole-mount immunostaining, samples were fixed in 4% formal-
dehyde in PBS for 2 hours on ice. After washing twice in PBS, samples 
were permeabilized in PBS 0.1% TritonX-100 (PBST) and satu-
rated for 2 hours in PBS containing 0.1% TritonX-100 and 3% milk 
(PBSMT) at RT. After washing twice in PBS, samples were incubated 
with primary antibodies: anti-mouse podoplanin from Developmental 
Studies Hybridoma Bank at 0.3 μg/mL; rabbit anti-mouse Lyve-1 
(Interchim 70R-LR005) at 2 μg/mL, and rat anti-mouse CD31 (BD 
553370) at 2.5 μg/mL in PBST overnight at 4°C with gentle agita-
tion. Samples were washed every 15 minutes during 3 hours in PBST 
and incubated overnight at 4°C with secondary antibodies in PBST. 
Samples were then washed as described for the primary antibodies 
and mounted in Mowiol (Mowiol 4–88; Hoechst) supplemented with 
2.5% antibleaching agent DABCO (Sigma-Aldrich, France). Images 
were recorded using an LSM780 laser scanning confocal microscope 
(Zeiss). Negative controls were performed with no primary antibody.
Dermis Size Quantification
Dermis size quantification was performed using 10 measurements of 
the length between epidermis and hypodermis per field, 6 tissue sec-
tions per mice, and 5 mice per group.
Transcription Factor Motif Identifications
Annotation of the promoter regions of Figf, Flt4, Has1, Has2, and 
Lyve1 genes was performed under the gene search algorithm included 
in the motifmap webservice (http://motifmap.ics.uci.edu/).28 We ana-
lyzed the DNA sequences (mm9 genome annotation) corresponding 
to the −5000/+1000-bp region surrounding the transcription start-
ing site of each gene to search for transcription factor-binding sites. 
To ensure statistical significance, we retained as putative binding 
sites only those determined with a Z score >2 and an FDR thresh-
old <0.5. The DNA sequence corresponding to motifs resembling 
to ER-binding sites (binding sequences for Hnf4α and other nuclear 
receptors) was retrieved from the UCSC browser (http://genome.
ucsc.edu/)29 and additionally visually inspected for its correspon-
dence with known ER motifs.
Cell Culture
Human dermal LECs (HDLECs; Promocell, Heidelberg, Germany) 
were cultured in endothelial growth medium MV2 containing 5% 
FBS (Promocell). Twenty-four hours before the experiments, culture 
media was replaced by endothelial growth medium MV2 phenol red 
free. Survival assay was performed using 1 nM 17β estradiol and 1 M 
tamoxifen. Proliferation, migration, and branching assays were per-
formed as described previously.30 Positive control consists in 5% FBS 
and negative control consists in 0.5% serum with ethanol (1/1000).
Microwave Sensor
Mice were anesthetized with a subcutaneous injection of ketamine 
(100 mg/kg) and xylazine (10 mg/kg), and 5 measures were per-
formed on 5 different locations to cover the entire edematous area. 
For each of them, a pulse of microwaves from 0 to 1.5 gHz frequency, 
the incident wave, was applied to skin. Skin components, including 
fluids and ions, will thus either absorb or reflect a part of theses waves 
to induce a reflected wave. Reflected wave reflection, absorption, and 
delay were analyzed on each measure to determine the reflection 
coefficient phase of the skin. This coefficient directly correlates with 
the quantity of tissue fluids.
Permeability Assay
LECs were cultured under confluence for 3 days on cell culture 
inserts (0.4 μM, Millicell) and then treated overnight with estradiol 
or Tamoxifen in 0.5% serum phenol-free medium as indicated in the 
figures. FITC-dextran 70 KD (1 mg/mL) was added and fluorescence 
intensity was measured at 30 minutes or 1 hour after in lower cham-
ber by Tecan Infinite 500.
Western Blot Analysis
Cells were harvested on ice, washed twice with cold PBS, col-
lected, and frozen at −80°C. Dry pellets of cells were lysed in 50 
mmol/L Tris-HCl, pH 7.5, 150 mmol/L NaCl, 1 mmol/L EDTA, 1% 
TritonX-100 (X100; Sigma) supplemented with protease and phos-
phatase inhibitors (sodium orthovanadate [S6508; Sigma], 1 mmol/L 
DTT, 2 mmol/L NaF [S1504; Sigma], and complete Mini Protease 
Inhibitor Cocktail [ROCHE]). Protein concentration was measured 
using BCA Protein Assay Kit (Interchim), and equal amounts of 
proteins were subjected to SDS-PAGE and transferred onto nitro-
cellulose membrane (BioTraceNT, Pall Corp). Membranes were 
washed in Tris-buffered saline supplemented with 0.1% Tween-20 
and then saturated in Tris-buffered saline supplemented with 0.1% 
Tween-20 with 5% nonfat dry milk, incubated overnight with primary 
antibodies in Tris-buffered saline supplemented with 0.1% Tween-
20 with 5% BSA, washed and revealed according to Cell Signaling 
Technology protocol. Western blotting was conducted using standard 
methods with the following antibodies: p-Akt S473 (cat No. 4060, 
1:2000; Cell Signaling Technology), pan-Akt (cat No. 4691S, 1:1000; 
Cell Signaling Technology), p-ERK1/2 (cat No. 4370, 1:1000; Cell 
Signaling Technology), GAPDH (6C5; cat No. sc-32233, 0.1 μg/mL; 
Santa Cruz Biotechnology), and ERα clone 60C (N-term; cat No. 
04–820, 1:2000; Millipore).
Statistical Analysis
All statistical analyses were performed using either a 2-tailed 
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of ≥3 groups. One-way ANOVA was followed by post hoc test of 
Bonferroni (Figures 1C, 1D, 2B, and 3A). All experiments were per-
formed 3×, where the quantification is reported as the average ±SEM 
of 3 separate animal experiments, *P<0.01, **P<0.001.
Results
ERα Targets Lymphangogenic Genes
To determine whether the receptor ERα could control lym-
phatic-related genes, we first screened the sequences of the 
promoter regions of VEGF-D, VEGF-C, VEGFR-3, Lyve-1, 
and HAS to identify potential DNA motifs able to mobilize 
ER (full or half-ERE and AP1; Figure 4A). We found ERE or 
half-ERE in all genes except for VEGF-C (Figure 4A; Table I 
in the online-only Data Supplement). VEGF-D and VEGFR-3 
both contain a putative binding site for ER in their first intron. 
Hyaluronan receptor Lyve-1 and HAS-1 and HAS-2 were 
identified as containing AP1 and ERE/half-ERE sequences, 
respectively (Figure 4A). These data suggested a putative 
gene regulation by the ER. To confirm the regulation, we stud-
ied gene expression in vivo in estradiol-treated mice. Mice 
were ovariectomized at 4 weeks of age and implanted either 
with 17β estradiol pellets (80 μg/kg per day) or with placebo-
releasing pellets. Treatment was validated by the increase in 
uterine weight in estradiol-treated ovariectomized animals 
Figure 1. Mice experimental model of surgery-induced secondary lymphedema. A, Schematic representation of the experimental pro-
cedure. Mastectomy and lymphadenectomy are performed in 6-wk-old mice. B, Swelling develops 2 wk after surgery in proximal (left) 
and distal (right) part of the leg. C, Quantification of the proximal leg swelling revealing lymphedema 2 wk after surgery (n=10). *P<0.01. 
D, Quantification of the distal leg swelling. *P<0.01. E, Masson trichrome staining of the skin from mice with lymphedema (scale bar=50 
μm). F, Fibrosis quantification (blue pixels) normalized to normal skin. *P<0.01. G, Mouse lymphedema exhibits increase of dermis size 2 
wk after surgery, *P<0.001. H, Fluorescence microlymphangiography revealed an altered lymphatic drainage in lymphedema (left) that is 
not associated with collecting vessel disruption (right; scale bar=25 μm). I, Footpad FITC-dextran injection shows capillary dermal back-
flow in lymphedema (scale bar=50 μm). J, Relative quantification of dermal leakage in lymphedema. *P<0.001. K, Electric properties of 
lymphedematous skin exhibit strong frequency dispersion in microwave bands, which translate into a specific signature as consequent 
of microwave radiation reflection and absorption. Lymphedematous leg exhibits delay in microwave reflection coefficient phase (n=5). 
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(Figure IA and IB in the online-only Data Supplement), and 
quantitative real-time PCR was performed on skin mRNA 
(Figure 4B through 4E). As expected, we found an upregula-
tion of VEGF-D (Figure 4B), VEGFR-3 (Figure 4C), Lyve-1 
(Figure 4D), and HASs (Figure 4E) in estradiol-treated ani-
mals. This upregulation was associated with an increase in skin 
lymphangiogenesis (Figure 4F and 4G). To confirm that estra-
diol could modify lymphatic-related genes in the lymphatic 
endothelium, we investigated the expression of LYVE-1 and 
VEGFR-3 in LECs in vitro. We first confirmed by quantitative 
real-time PCR and Western blot that HDLECs express only 
the receptor ERα, but not Erβ, suggesting a selective effect 
of this receptor in lymphatic endothelium (Figure IC and ID 
in the online-only Data Supplement). As HDLECs are iso-
lated from male foreskin, we wondered whether sex gender 
could influence the ERα expression in tissues to eliminate 
bias related to gender cell origins (Figure IE in the online-only 
Data Supplement). As expected, we could not find any tissue-
specific variation between male and female. Interestingly, we 
found an activation of Lyve-1 and VEGFR-3 mRNA expres-
sion in estradiol-stimulated HDLEC (Figure 4H and 4I). To 
further demonstrate that the effect of estradiol is mediated 
by ERα, ERα was knocked down using shRNA in HDLECs 
(Figure 4J). The depletion of ERα using shRNA abolished the 
induction of the ERα-targeted gene VEGF-A induced by estra-
diol (Figure IF in the online-only Data Supplement). Also, the 
increase of VEGFR-3 and LYVE-1 expression induced by 
estrogen treatment was abolished in shERα-transfected cells 
confirming that ERα mediates lymphatic gene expression in 
LECs in response to estradiol (Figure 4K and 4L).
Mice Model of Secondary Lymphedema
To study whether estrogen level may influence lymphatic 
function in secondary lymphedema, we established an origi-
nal mouse model of lymphedema induced by second mam-
mary gland mastectomy associated with axillary and brachial 
lymphadenectomy on 6-week-old C57Bl/6 female mice 
(Figure 1A; Figure IIA in the online-only Data Supplement). 
In this model, mice sustained reproducible edema for a 
period of >2 weeks as limb volume measurements system-
atically peaked 2 weeks after the surgery procedure with a 
volume increase of 20% to 25% in proximal (axillary) and 
distal (foot) part of the leg (Figure 1B). Then, resolution 
of edema consistently occurred after 4 weeks (Figure 1C 
and 1D). Using Masson trichrome coloration, we observed 
clinical signs occurring in lymphedema, including skin 
fibrosis (Figure 1E and 1F) and increased dermis thickness 
(Figure 1G). Lymphatic circulation was next investigated 
in collecting vessels and in capillaries using intralymphatic 
injection of dextran-FITC. The overall lymphatic perfusion 
was decreased in lymphedematous limb without any effect on 
collecting vessel shape (Figure 1H). In contrast, we observed 
an important lymphatic leakage (dermal backflow) in superfi-
cial capillary network (Figure 1I) as shown by the lymphatic 
leakage score (Figure 1J). Early detection of lymphedema is 
a major challenge in the patient health care. For this purpose, 
we developed an original device based on microwave reflec-
tion analysis to detect early swelling (Figure 1K; Figure IIB 
in the online-only Data Supplement). Microwave relies on the 
specific electric properties of living tissues, such as skin, mus-
cle, fat, and many others, which are different from those of 
gazes (air) or other solid and nonbiological material (glass or 
plastic). We observed a shift in reflection coefficient phase rel-
ative to limb edema (Figure 1K). This alteration of lymphatic 
function in our mice model of lymphedema was accompanied 
by an increase of lymphatic vessel density in skin (Figure 1L 
and 1M) indicating a strong activation of lymphangiogenesis 
during the onset of lymphedema.
Secondary Lymphedema Is Prevented by Estrogens 
but Is Aggravated by Tamoxifen Treatment
Deciphering whether estrogen could play a role in lymphatic 
function remains a crucial challenge for breast cancer-related 
lymphedema because for decades, selective ER modulators, 
such as tamoxifen, are used in first line of hormone therapy 
for women who develop breast cancer. Toward this aim, mas-
tectomy and lymph node dissection were performed on OVX 
mice implanted with estradiol, tamoxifen, or placebo pellets 
2 weeks before surgery (Figure 2A). Remarkably, edema was 
observed in OVX group and was exacerbated by blocking 
ERα using tamoxifen. Notably, the protective effect of estra-
diol on lymphedema was abolished by tamoxifen, and lymph-
edema was maintained 4 weeks after surgery (Figure 2B). 
Estradiol and tamoxifen did not induce modifications of the 
basal lymphatic network architecture in ear skin (Figure 
III in the online-only Data Supplement). In contrast, in the 
context of lymphedema, we observed an induction of skin 
lymphangiogenesis in both estradiol and tamoxifen-treated 
groups (Figure 2C and 2D). Despite an absence of modifica-
tion in lymphatic vessel density between estradiol and tamoxi-
fen treatment, we observed an important lymphatic leakage 
(arrows) in superficial capillaries network in OVX mice that 
was prevented by estradiol treatment showing a protective 
effect of estradiol on the endothelial barrier (Figure 2E). 
On the opposite, tamoxifen aggravated the dermal backflow 
that was, in part, reduced by estradiol (Figure 2E and 2F). 
Interestingly, deeper lymphatic collecting vessels were not 
affected by tamoxifen confirming an impact restricted to the 
capillary network (Figure 2G). This effect was associated with 
changes in water and ion contents as assessed using micro-
wave sensor showing a shift between estradiol and tamoxifen 
(Figure 2H).
Estrogens are potent anti-inflammatory regulators of cuta-
neous healing.31 To evaluate whether estradiol and tamoxi-
fen could have an effect on the inflammatory status, immune 
response was analyzed by flow cytometry in brachial and 
axillary lymph nodes to evaluate the systemic inflammation 
(Figure 2I and 2J). Estradiol partially decreased F4/80-positive 
macrophages, and this effect was not abolished by tamoxifen 
(Figure 2I). Lymphatic injury increased the number of macro-
phages and favored M2 differentiation as observed previously 
in the mouse tail model of lymphedema.32 Our findings sug-
gest that macrophages home to lymphedematous tissues and 
differentiate into the M2 phenotype. Surprisingly, tamoxifen 
had no major effect compared with estradiol on the inflam-
matory process in our model (Figure 2J). As we previously 
demonstrated the role of estradiol on controlling lymphan-
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could abolish the effect of estradiol on lymphedematous skin. 
Mechanistically, we found that tamoxifen blocked estradiol-
induced VEGF-D (Figure 2K), VEGFR-3 (Figure 2L), Lyve-1 
(Figure 2M), and HAS (hyaluronan synthases)-1, HAS2, 
and HAS3 (Figure 2N) gene expression. Taken together, 
our results highlight that estrogen plays a protective role on 
lymphatic endothelium during the pathological condition of 
lymphedema.
Figure 2. Tamoxifen (TMX) inhibits beneficial effect of estrogen on lymphatic endothelium. A, Schematic representation of the experimen-
tal procedure. Sixty-day released estradiol (E2) or TMX subcutaneous pellets are implanted 2 wk before lymphedema surgery. B, Mice 
proximal leg diameter measurement shows that TMX aggravates swelling and inhibits the reduction of edema 4 wk after surgery (n=10). 
C, Skin immunodetection of the lymphatic vessels in E2 or TMX-treated lymphedematous leg (scale bar=50 mm). D, Quantification of lym-
phatic vessel density. E, FITC-dextran intralymphatic injections revealed leaky lymphatic capillaries in edematous skin in that is reduced 
by E2 and aggravated by TMX (scale bar=50 μm). F, Relative quantification of the leakage shows that E2-improved lymphatic drainage 
is antagonized by TMX. G, FITC-dextran intralymphatic injections revealed that TMX did not induce collecting vessels leakage. H, The 
deleterious effect of TMX is characterized by a delay in microwave reflection. I and J, Flow cytometry analysis of the F4/80-positive (I) 
and M1/M2 macrophages (J) in E2- or TMX-treated mice with 4-wk lymphedema. K, Quantitative real-time polymerase chain reaction (RT-
PCR) shows that TMX inhibits E2-induced VEGF (vascular endothelial growth factor)-D but not VEGF-C expressions. L–N, Quantitative 
RT-PCR shows that TMX inhibits E2-induced VEGFR-3 (L), Lyve-1 (M), and HAS (hyaluronan synthase)-1, 2, and 3 (N) mRNA expression 
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Protective Effect of Estrogens on Lymphatic 
Endothelium Is Mediated by ERα
To better understand the role of ERα on the lymphatic sys-
tem, we performed experiments in mice deleted for ERα 
in the endothelium using the Tie2-Cre; ERαlox/lox mice 
model.33,34 The deletion of ERα in the lymphatic endothe-
lium was validated in Tie2-Cre; mTmG mice (Figure IV in 
the online-only Data Supplement). No significant difference 
in VE-cadherin button-like junctions was observed in lym-
phatic capillaries from Tie2-Cre; ERαflox/flox mice compared 
with control ERαflox/flox mice (Figure VA in the online-only 
Data Supplement). In parallel, the KI-67 immunodetection 
did not reveal major modification in skin vessel proliferation 
in Tie2-Cre; ERαflox/flox mice compared with control (Figure 
VB in the online-only Data Supplement). In lymphedema 
model, we observed an inhibition of the protective effect of 
estradiol in estradiol-treated Tie2-Cre; ERαlox/lox mice because 
the edema is induced 2 weeks after surgery, despite the estro-
gen treatment (Figure 3A). As observed with tamoxifen, the 
edema was maintained after 4 weeks, whereas it was resolved 
in ERαlox/lox estradiol-treated mice (Figure 3A). The inhibition 
of the protective effect of estradiol on lymphatic endothe-
lium was confirmed by intralymphatic dye injection show-
ing an important dermal backflow in Tie2-Cre; ERαlox/lox mice 
compared with ERαlox/lox (Figure 3B and 3C). As we previ-
ously showed that estradiol regulates VEGFR-3 and LYVE-1 
gene expression in vivo and in vitro (Figure 4), we first ana-
lyzed expression of these genes by quantitative real-time 
Figure 3. Estrogen-protective effect on lymphatic endothelium is mediated by the estrogen receptor (ER) α. A, Leg measurement shows 
an inhibition of estradiol (E2)-protective effect on lymphedema in Tie2-Cre; ERαlox/lox mice. B, Footpad FITC-dextran injection shows der-
mal backflow in Tie2-Cre; ERαlox/lox mice lymphedema treated with E2. C, Leakage score quantification Tie2-Cre; ERαlox/lox mice. D, Quanti-
tative real-time polymerase chain reaction on Tie2-Cre; ERαlox/lox mRNAs from sorted lymphatic endothelial cells (LECs) show an inhibition 
of VEGFR (vascular endothelial growth factor receptor)-3, Lyve-1, TGFb, VEGF-A, and ERα expression compared with ERαlox/lox LECs. E, 
Immunostaining for CD31 and VEGFR-3 shows a decrease of VEGFR-3 expression on lymphatic capillaries in Tie2-Cre; ERαlox/lox mice 
(scale bar=200 μm). F, Quantification of VEGFR-3 immunodetection on lymphatic vessels. G, Immunostaining for Lyve-1 (green), podo-
planin (red), and CD31 (blue) in control skin revealed dilated lymphatic vessels in Tie2-Cre; ERαlox/lox mice compared with control ERαlox/lox 
mice (scale bar=200 μm). H, Immunostaining for podoplanin in lymphedematous skin shows dilated lymphatic vessels in Tie2-Cre; ERαlox/
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PCR in isolated LECs from Tie2-Cre; ERαlox/lox mice. LEC 
sorted from these mice exhibited a decrease in VEGFR-3 
and Lyve-1 mRNA, as well as ER-targeted genes, such as 
TGFβ and VEGF-A, and ERα expression (Figure 3D). In 
addition, decrease of VEGFR-3 expression was confirmed 
at protein level by whole-mount immunostaining on Tie2-
Cre; ERαlox/lox mice compared with ERαlox/lox mice (Figure 3E 
and 3F). Interestingly, the absence of ERα revealed enlarged 
and dilated vessels suggesting a higher permeability of the 
lymphatic endothelium (Figure 3G). Consequently, the loss 
of proper function of the lymphatic vessel observed in Tie2-
Cre; ERαlox/lox mice was aggravated in lymphedematous skin 
with the presence of enlarged and tortuous lymphatic vessels 
(Figure 3H and 3I).
Estradiol-Induced LEC Function In 
Vitro Is Mediated by Erk Pathway
Because dilated and permeable lymphatic vessels observed in the 
absence of ERα signaling (Figure 3) or on tamoxifen treatment 
(Figure 2) may relate to an alteration in the junctional organiza-
tion of lymphatic vessels, we first wondered whether estradiol 
could modulate LEC cell–cell junctions in vitro (Figure 5A). 
Intriguingly, estradiol preserves LEC junctions at a comparable 
level to serum treatment (Ctrl+). In contrast, tamoxifen down-
regulates VE-cadherin at membrane level, and this effect cor-
related with a decrease in cortical actin fibers (Figure 5A). In 
the context of lymphedema, we previously showed that estrogen 
signaling is required to repair a functional lymphatic network. 
Therefore, we next investigated the role of estradiol on LEC 
Figure 4. ER (estrogen receptor)-α targets lymphangogenic genes. A, Schematic representation of ER-binding sites (estrogen response 
element [ERE] and AP1) on VEGF (vascular endothelial growth factor)-D, VEGFR-3, Lyve-1, HAS (hyaluronan synthase) 1, and HAS2 on 
−5000/+1000-bp region surrounding the transcription starting site. B–E, Quantitative real-time polymerase chain reaction (RT-PCR) of 
VEGF-C and VEGF-D (B), VEGFR-3 (C), Lyve-1 (D), and HAS1, 2, and 3 (E) mRNAs in skin from mice treated with estradiol (E2) during 28 
d and compared with control (NL) or OVX (ovariectomized) mice. F, Skin immunodetection of the lymphatic vessels in E2-treated mice 
(4-wk treatment) compared with OVX and non-OVX mice (scale bar=100 mm). G, Quantification of lymphatic vessel density in the skin 
from E2-treated mice compared with OVX and non-OVX. H and I, Quantitative RT-PCR of Lyve-1 (H) and VEGFR-3 (I) mRNAs in E2-stim-
ulated human dermal lymphatic endothelial cells (HDLECs) compared with 0.5% SVF (C−) or 5% SVF (C+). J, Quantitative RT-PCR of ERα 
mRNA in HDLEC after ERa shRNA transfection. K, Quantitative RT-PCR of VEGFR-3 mRNA in HDLEC after ERα shRNA transfection. L, 
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functions in vitro by performing survival, migration, branch-
ing, and permeability assays (Figure 5B through 5F).35 Blocking 
ERαv with tamoxifen did not alter cell survival (Figure 5B). We 
found that tamoxifen inhibited estradiol-induced LEC migration 
both in scratch (Figure 5C) and transwell (Figure 5D) migra-
tion assays. The role of estradiol on LEC sprouting in matrigel 
was further evaluated (Figure 5E). Estradiol promoted an induc-
tion of LEC branching in vitro that was inhibited by tamoxifen 
(Figure 5E). In contrast, estradiol did not induce LEC monolayer 
permeability, whereas tamoxifen strongly promoted the transen-
dothelial diffusion of FITC-Dextran (Figure 5F).
Plasma Membrane ERα
There are 2 subcellular localizations of the ER: a nuclear 
localization that mediates its transcriptional activity and a 
plasma membrane localization that promotes activation of 
nongenomic signaling pathway (Figure 6A). To identify this 
nongenomic estradiol-induced signaling in LECs, we stud-
ied Akt and Erk phosphorylation in vitro (Figure 6B through 
6D). Immunoblot analysis of PS473-Akt and P-Erk on LEC 
showed a strong and rapid stimulation of the phosphoryla-
tion induced by estradiol after 30 minutes (Figure 6B). 
Surprisingly, tamoxifen did not antagonize estradiol-induced 
PS473-Akt phosphorylation (Figure 6C). In the opposite, 
tamoxifen inhibited estradiol-induced Erk phosphorylation, 
suggesting a pivotal role of Erk pathway in the beneficial 
effect of estradiol on lymphatic endothelium (Figure 6D). 
To confirm this hypothesis, LEC migration assays were per-
formed in presence of MEK inhibitor. We observed an inhibi-
tion of LEC migration in scratch (Figure 6E) and transwell 
Figure 5. Tamoxifen (TMX) inhibits lymphatic endothelial cell function in vitro. A, Phalloidin (green) and VE-cadherin (red) immunostaining 
on human dermal lymphatic endothelial cell (HDLEC) unstimulated (Ctrl: 0.5% SVF) or stimulated by VEGF (vascular endothelial growth 
factor)-C (Ctrl+: 30 ng/mL), estradiol (E2; 1 nM), and TMX (1 mmol/L) shows a slight increase of VE-cadherin expression with E2. TMX 
induces a downregualtion of VE-cadherin expression associated to an alteration of cortical actin organization at cellular junctions (scale 
bar=50 μm). B, E2 and TMX have no effect on HDLEC survival. C, Quantification of the percentage of HDLEC migration using scratch 
wound healing assay shows an inhibition of E2-induced migration by TMX. D, Quantification of the percentage of HDLEC migration using 
Boyden chamber shows an inhibition of E2-induced migration by TMX. E, TMX antagonizes E2-induced HDLEC branching in matrigel. F, 
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(Figure 6F) migration assays demonstrating the crucial role 
of Erk pathway in nongenomic estradiol-induced LEC activa-
tion. These data suggested that estrogens mobilize activation 
of 2 pools of ERα in LEC, both the canonical nuclear tran-
scriptional activity and the plasma membrane-induced signal-
ing cascade (Figure 6).
Discussion
Despite the large body of evidence showing that sex hor-
mones, in particular estrogens, influence lymphatic function, 
surprisingly little is known about the mechanisms of estro-
gen regulation on lymphatic endothelium. In this study, we 
identified a crucial role of estrogens in protecting lymphatic 
endothelium during secondary lymphedema. Then, we studied 
the impact of a selective ER modulator, tamoxifen, on lymph-
edema incidence. Estradiol is ubiquitous hormone generally 
thought to be a female hormone but is also produced in male 
and targets the organism in a same extent as estradiol response 
is observed in postmenopausal women, as well as in transgen-
der men. This response is associated with the expression of 
the receptor ERα that is similar in male and female. Here, we 
determined that the expression of ERα in LEC is restricted to 
the isoform α, which is a major difference with blood EC that 
express both ERα and β.36 Using genome analysis, we found 
that estradiol targets VEGFR-3, VEGF-D, Lyve-1, and HAS 
gene expression. Therefore, we postulated that blocking estro-
gen function might have a direct impact on lymphatic func-
tion and then in lymphedema. Estrogens have been known for 
decades to have beneficial effects on the skin because they rep-
resent critical regulators of dermal hyaluronan.37 Hyaluronan 
plays a key role in regulating lymphangiogenesis by providing 
the fundamental matrix for LEC function.38 To better dissect 
molecular mechanism involved in secondary lymphedema, 
we developed an original mouse model of unilateral second-
ary lymphedema. As we postulated that lymphedema is not 
only a side effect of surgery, we hypothesized that edema 
will worsen by hormone treatment. We found that estradiol 
prevents lymphedema development. This effect seems to be 
restricted to lymphatic capillaries because deeper collecting 
vessels are not affected by estrogen treatment. These observa-
tions are in opposite with the effect on blood microvascular 
vessels in which estradiol induces a rapid increase of perme-
ability because of the stimulation of VEGF-A gene expres-
sion.39–41 In fact, secondary lymphedema leakage is associated 
with a blockade of the lymph flow from the tissue to the 
lymphatic vessels leading to an accumulation of fluids into 
Figure 6. Tamoxifen (TMX) inhibits estradiol (E2)-induced ERK signaling. A, Schematic representation of TMX action on nuclear- and 
membrane-initiated effect of ER (estrogen receptor). B, Immunoblot of pS473-Akt, pErk1/2, and Akt in human dermal lymphatic endothe-
lial cells (HDLECs) stimulated by E2 and E2+TMX. C and D, Relative levels of phosphorylated S473Akt (C) and Erk1/2 (D) normalized to 
total Akt. E, Quantification of the percentage of E2-induced HDLEC migration using scratch wound healing assay shows an inhibition by 
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tissues. In that context, estrogens ameliorate lymphatic func-
tion and significantly reduce the dermal backflow.
Secondary lymphedema mostly occurs after breast can-
cer. Women with early-stage breast cancer receive ≤5 years 
of adjuvant treatment with tamoxifen—an inhibitor of ER. 
We found that blocking ERα using tamoxifen is an aggravat-
ing factor for lymphedema because swelling is not resolved 
compared with OVX or estradiol-treated mice. This delete-
rious effect of blocking ERα was confirmed using TieCre; 
ERαlox/lox mice that exhibit long-term swelling. These mice 
show a strong dermal lymphatic backflow associated with 
hyperplastic and dilated vessels representative of fluid stasis. 
Mechanistically, we found that loss of ERα reduces lym-
phangiogenic gene expression VEGFR-3 and LYVE-1 in 
vivo and in vitro. Therefore, it will be particularly interest-
ing to further investigate the function of ERα in lymphatic 
endothelium by generating ERα lymphatic-specific KO 
mice models to discriminate the lymphatic-specific effect 
of estradiol and its role on extracellular matrix remodel-
ing. The selective inhibition of ERα in LEC by tamoxi-
fen did not affect survival or proliferation demonstrating a 
major discordance with mammary epithelial cells in which 
tamoxifen induces apoptosis.42 Traditionally, estrogen sig-
naling is thought to be mediated through genomic pathways. 
However, estrogen stimulation of cells leads to rapid nonge-
nomic effects, including Akt and Erk phosphorylation. Here, 
we demonstrated that estradiol-induced Erk, but not Akt 
phosphorylation, is inhibited by tamoxifen in LECs. One of 
the main consequences of estrogen inhibition in vitro is to 
inhibit LEC migration and tube formation.
Altogether, these observations suggest that hormone ther-
apy interferes with lymphatic vasculature stability, more than 
lymphatic growth. These data are in accordance with human 
secondary lymphedema that develop months, sometimes years, 
after surgery demonstrating a preexisting, even dysfunctional, 
lymphatic system. Hormone therapy could thus increase the 
lymphatic dysfunction more than lymphatic regeneration 
immediately after surgery. This deleterious effect is aggravated 
by a stimulus years after surgery that induces a disruption of this 
damaged endothelium to induce a massive leakage. Our study 
establishes the pivotal role of hormones, in particular estrogens, 
in the healing of the lymphatic endothelium. It will provide 
significant knowledge to better anticipate and understand the 
pathology to improve the medical aspects of patient care.
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Highlights
• Estrogens play a crucial role in lymphatic vessel function.
• Estrogens protect from lymphedema through its receptor ER (estrogen receptor)-α.
• Chronic long-term delivery of tamoxifen has a deleterious impact on lymphatic vessels.
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